These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30411339)

  • 41. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
    Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
    Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
    Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
    Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Occhiuto CJ; Liby KT
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
    Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
    Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function.
    Takahashi J; Suzuki T; Sato M; Nitta S; Yaguchi N; Muta T; Tsuchida K; Suda H; Morita M; Hamada S; Masamune A; Takahashi S; Kamei T; Yamamoto M
    Cell Rep; 2024 Apr; 43(4):114104. PubMed ID: 38602872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methylseleninic acid activates Keap1/Nrf2 pathway via up-regulating miR-200a in human oesophageal squamous cell carcinoma cells.
    Liu M; Hu C; Xu Q; Chen L; Ma K; Xu N; Zhu H
    Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26341629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
    Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas.
    Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Mol Med Rep; 2012 Aug; 6(2):391-4. PubMed ID: 22614957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
    Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
    Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
    Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
    J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Emmanuel N; Li H; Chen J; Zhang Y
    Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
    DeBlasi JM; Falzone A; Caldwell S; Prieto-Farigua N; Prigge JR; Schmidt EE; Chio IIC; Karreth FA; DeNicola GM
    Cancer Res; 2023 Jun; 83(12):1953-1967. PubMed ID: 37062029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
    Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
    J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo.
    Suzuki T; Maher J; Yamamoto M
    Cancer Res; 2011 Mar; 71(5):1700-9. PubMed ID: 21177379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
    Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
    Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
    Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
    PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. "Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.
    Best SA; Sutherland KD
    Cell Cycle; 2018; 17(14):1696-1707. PubMed ID: 30009666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.